Williford S L, Bernstein S A
Department of Family Practice Womack Army Medical Center, Ft. Bragg, NC 28307, USA.
Pharmacotherapy. 1996 Jan-Feb;16(1):66-74.
Desmopressin is a commonly used, well-tolerated agent for the treatment of primary nocturnal enuresis and central diabetes insipidus. Intranasal desmopressin provides symptomatic relief with few serious complications. A 29-year-old woman with a long history of primary nocturnal enuresis began treatment with intranasal desmopressin. Although the enuresis ceased, she developed throbbing headaches, nausea, vomiting, paresthesia, lethargy, fatigue, and altered mental status over the next 7 days. When she came to the emergency room her sodium concentration was 127 mmol/L. The history of desmopressin use was not obtained at that time. She was treated with intravenous fluids and discharged. The symptoms returned and worsened over the next 4 days, and she returned to the emergency room stuporous. A repeat sodium was 124 mmol/L, and she was admitted. The history of desmopressin use was still not available. Medical evaluations included computerized tomography, lumbar puncture, complete blood counts, serum chemistries, and serologies. The next morning the woman was improved and informed clinicians of her desmopressin use. Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin. Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved. A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status. Our patient illustrates the importance of early recognition and treatment of hyponatremia before the onset of seizures. When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis. It may also be prudent to screen for electrolyte abnormalities in patients taking this agent to prevent serious iatrogenic complications.
去氨加压素是治疗原发性夜间遗尿症和中枢性尿崩症常用且耐受性良好的药物。鼻内使用去氨加压素能缓解症状且严重并发症较少。一名有原发性夜间遗尿症病史多年的29岁女性开始使用鼻内去氨加压素治疗。虽然遗尿症停止了,但在接下来的7天里,她出现了搏动性头痛、恶心、呕吐、感觉异常、嗜睡、疲劳和精神状态改变。当她来到急诊室时,她的血钠浓度为127 mmol/L。当时未了解到使用去氨加压素的病史。她接受了静脉补液治疗后出院。症状在接下来的4天里再次出现且加重,她再次昏迷着回到急诊室。复查血钠为124 mmol/L,她被收治入院。仍未获取到使用去氨加压素的病史。医学评估包括计算机断层扫描、腰椎穿刺、全血细胞计数、血清化学检查和血清学检查。第二天早上,该女性病情好转,并告知临床医生她使用了去氨加压素。由于低钠血症没有其他病因,她被诊断为抗利尿激素分泌不当综合征,推测是由去氨加压素引起的。在限液和停用去氨加压素后的24小时内,她的症状和低钠血症得到缓解。文献回顾发现有11名儿童和2名成人鼻内使用去氨加压素后出现低钠血症,他们均出现了癫痫发作或精神状态改变。我们的患者说明了在癫痫发作前早期识别和治疗低钠血症的重要性。当在去氨加压素治疗期间出现模糊症状时,必须将低钠血症作为鉴别诊断的一部分来考虑。对服用该药物的患者进行电解质异常筛查可能也是谨慎之举,以预防严重的医源性并发症。